Lung cancer is the leading cause of cancer-related death worldwide. Thus, developing novel therapeutic agents has become critical for lung cancer treatment. In this study, compound AS7128 was selected from a 2-million entry chemical library screening and identified as a candidate drug against non-small cell lung cancer in vitro and in vivo. Further investigation indicated that AS7128 could induce cell apoptosis and cell cycle arrest, especially in the mitosis stage. In addition, we also found that iASPP, an oncogenic protein that functionally inhibits p53, might be associated with AS7128 through mass identification. Further exploration indicated that AS7128 treatment could restore the transactivation ability of p53 and, thus, increase the expressions of its downstream target genes, which are related to cell cycle arrest and apoptosis. This occurs through disruption of the interactions between p53 and iASPP in cells. Taken together, AS7128 could bind to iASPP, disrupt the interaction between iASPP and p53, and result in cell cycle arrest and apoptosis. These findings may provide new insight for using iASPP as a therapeutic target for non-small cell lung cancer treatment.
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| INTRODUCTION
Lung cancer remains the leading cause of cancer-related death worldwide. 1, 2 Although people are paying more attention to preventive medicine, an estimated 1.8 million new cases of lung cancer are diagnosed each year, and most of them are non-small cell lung cancer (NSCLC). Although target therapies are improving the clinical outcomes of lung cancer, the occurrence of drug resistance is a critical challenge. 3 Thus, new therapeutics are needed.
In general, cancer occurs due to an alteration of cell division, which is an important process that lets cells grow, replicate their DNA and divide. The cell cycle process is usually controlled by complicated signaling pathways that include many regulators, such as p53. This regulator may protect the genome through its role in maintaining stability by ensuring that replication errors are corrected. 4 As such, malfunctions of p53 may interfere with cell cycle arrest, apoptosis, senescence and autophagy. 5 Several studies indicate that the activity of p53 is suppressed through binding of murine double minute 2 (MDM2) and inducing p53 proteasome degradation. 6 In addition, a high mutation rate of p53 has been detected in a majority of cancers. 7 The mutant p53 may acquire oncogenic functions through alterations in its DNA binding ability, changes in the associated protein network or interference with its downstream gene expressions. 8, 9 In addition to cell proliferation, p53 is involved in the regulation of the epithelial-tomesenchymal transition and cancer stem cell features. [10] [11] [12] Hence, the restoration of wild-type p53 activity could be a path for developing novel anticancer therapeutics.
Emerging evidence shows that iASPP, which is encoded by the PPP1R13L gene, is overexpressed in various cancers. [13] [14] [15] [16] [17] The family of apoptosis-stimulating proteins of p53 (ASPP) consists of ASPP1, ASPP2 and iASPP. The first 2 are considered as common activators of p53 that can enhance cell apoptosis, whereas iASPP acts as an inhibitor that can suppress the apoptotic transactivation potential of p53 by direct interaction. 18 iASPP can also inhibit the apoptotic activity of p63 and p73 and promote p53-independent carcinogenesis. 19, 20 In general, iASPP can be divided into 2 isoforms, which have 407
and 828 amino acids. The shorter one is a nuclear protein, and the longer one is located in both the cytosol and the nucleus. 10, 21 Nuclear iASPP may facilitate tumor progression and correlate with poor clinical outcome in prostate cancer and melanoma. 22, 23 All of the evidence suggests that targeting iASPP may be a feasible way to restore the function of p53. This idea was supported by 2 studies of p53-derived peptides, 37AA and A34, which can disrupt the interaction of iASPP with p73 and p53, respectively. 20, 24 Recently, a 2-step high-throughput screening of several lung cancer cells with different EGFR status was performed in our laboratory. 25, 26 AS7128, a 2-anilino-4-amino-5-aroylthiazole compound, was one of the candidates selected for its activity against lung cancer cell growth with a reasonable therapeutic window compared with a control. In this study, we explored the potential mechanisms of AS7128 in vitro and in vivo. We present the interesting finding that AS7128
can inhibit lung cancer cell growth through restoring the activity of p53 by targeting iASPP. This may provide a new insight to develop novel therapeutics for NSCLC treatment in the future.
| MATERIALS AND METHODS

| Cell lines and culture conditions
The human lung cancer cell lines A549 (adenocarcinoma, ATCC CCL- (100 units/mL) and streptomycin (100 lg/mL). The cells were grown at 37°C in a humidified atmosphere of 5% CO 2 and 95% air.
| Chemical library
The 2-million screening compound library contains commercial synthetic molecules, known bioactive inhibitors and approved drugs, pure natural products, and proprietary collections. The synthetic molecules in the 2-million library can be clustered into approximately 5300 groups, based on 85% structure similarity. The diversity is approximately 0.87, calculated using a modified centroid-diversity sorting algorithm. Compounds were prepared at 1 mmol/L in 100% DMSO in 1536-well propylene plates.
| Xenograft tumor growth in vivo
Experiments were carried out using BALB/c-nu mice, and all of the animal procedures were in accordance with the procedures and guidelines of the Institutional Animal Care and Use Committee. A total of 3 9 10 6 H1975 human lung cancer cells were subcutaneously injected into the flank of 6-week-old BALB/c-nu mice (purchased from BioLABSCO, Yilan, Taiwan). Three days after the inoculation with cancer cells, the animals were divided into 4 groups. Seven days after tumor implantation, both vehicle and 3 doses of AS7128 were suspended in 50% PEG400 (in PBS) and given intraperitoneally to the animals twice a week for 18 days. Body weight and tumor size were measured each time before drug delivery.
The tumor volume was calculated using the largest diameters (a) and smallest diameters (b) as V = 0.5 9 ab 2 . In addition, mice sera were collected to examine the levels of glutamate oxaloacetate transaminase (GOT), glutamate pyruvate transaminase (GPT), blood urine nitrogen (BUN) and creatinine (CREA) after the mice were sacrificed. HE stain was purchased from the National Taiwan clarified by centrifugation. The supernatants were taken as the total cell lysates. The compound-associated proteins were immunoprecipitated using AS7128 conjugated magnetic beads (which were synthesized as in Figure S1 and Data S1). The immunoprecipitated proteins were separated by SDS-PAGE, and the proteins were identified in a selected region by mass spectrometry.
The isolated gels were subjected to trypsin digestion and analyzed by mass spectrometry (LTQ-orbitrap XL; Institute of Biological Chemistry, Academia Sinica, Taiwan). The protein identification was processed by Proteome Discoverer software workflow (Thermo Fisher Scientific) using the Mascot search engine against the Swiss-Prot Homo sapiens protein database. Non-specific binding protein were eliminated from control group first. The remaining interactors were mapped using the CRAPome database 27 and a recent study 28 to determine the contaminant frequency of observations across AP-MS; and those frequency more than 15% were also be eliminated as the non-specific binders in this filter step. Then, the confidental interacting proteins were used to enrich their biological process annotations by Gene
Ontology (GO) analysis; and we finally selected the potential targets more focusing on those related to apoptosis-and cell-cycle-related proteins (detailed proteins are listed in Tables S1 and S2 ).
| Real-time quantitative RT-PCR
Total RNA was extracted from cells and reverse transcribed using SuperScript III Reverse Transcriptase (Thermo Fisher Scientific) and Random Hexamer primers (Thermo Fisher Scientific) in the presence of an RNase inhibitor according to the manufacturer's instructions.
The detection primers of each gene are shown in Table S3 . The reaction signals were detected by SYBR Green reagent (Thermo Fisher Scientific), and TATA-Box Binding Protein (TBP) was used as an internal control (GenBank X54993). The expression level of the detection gene relative to that of TBP was defined as -dCt = À[Ct of Gene À Ct of TBP], and the ratio was calculated as 2
ÀdCt
. Experiments were performed in duplicate, and no-template controls were included in each assay.
| Statistical analysis
The data are presented as the means AE SD or SEM, and the significance of differences was analyzed using Student's t test. All experiments were performed in triplicate, the statistical testing was 2-tailed, and P < .05 was considered statistically significant.
The details of other methods are listed in Data S1.
3 | RESULTS
| Identification of AS7128 that possesses nonsmall cell lung cancer inhibitory activities
Through high-throughput screening, we identified the 2-anilino-4-amino-5-aroylthiazole-type compound AS7128, which has the chemical structure shown in Figure 1A . The data are presented as the mean AE SEM and were analyzed using Student's t-test. Asterisks represent statistically significant differences (*P < .05). E, Tumor photographs after sacrifice (upper panel). Scale: 1 cm. Tissue morphology was examined by HE staining (lower panels). Scale: 50 lm. F, Cell apoptosis status was examined by TUNEL staining. Scale: 50 lm We also examined the expression levels of several cell cycle checkpoints, including cyclin D1, E, A and B1 and phospho-histone H3. As shown in Figure 2D , the expressions of cyclin B1 and serine 10 in phospho-histone H3 were increased after H1975 cells were treated with AS7128. Collectively, the data suggest that treatment with AS7128 might induce cell apoptosis through cell cycle G2/M arrest in H1975 cells.
| AS7128 arrested H1975 cell in M phase
To examine the events of AS7128-induced cell cycle arrest, H1975
cells were synchronized at the G1/S transition by double thymidine block and subsequently released into fresh medium containing DMSO or 250 nmol/L of AS7128 for 12 hour. The cell cycle statuses were monitored each hour by measuring the DNA contents with PI staining. As expected, cells treated with AS7128 were arrested in the G2/M phases, but most of the control cells reentered the G1 phase at 12 hour after release ( Figure 3A) .
We reperformed the same experiment and extended the releasing time to 18 hour to clarify whether the arrested H1975 cells could pass the G2/M phases after releasing for 12 hour under AS7128 treatment. The results showed that most of the H1975 cells were still arrested in the G2/M phases after 18 hour of release with AS7128 treatment ( Figure S3 ). This result was further confirmed by examining the protein expression levels of different cell cycle checkpoints. As shown in Figure 3B , the expressions of cyclin B1 and serine 10 in phistone H3 (2 specific G2 and M phase markers) were significantly increased in treated cell lysates compared with the control. 
| iASPP might be the action target of AS7128
Because AS7128 treatment could cause cell cycle arrest in the prophase and induce cell apoptosis, we investigated its mechanism of action. AS7128 was conjugated into magnetic beads ( Figure 4A ) and 27, 28 In addition, GO enrichment analysis revealed that 36 of these proteins were involved in cell apoptosis or cell cycle regulation ( Figure S4B and Table S2 ). Among them, we chose the 2 proteins iASPP and CSE1L for further validation, which are related to p53-induced cell apoptosis. The results showed that iASPP but not CSE1L could be co-immunoprecipitated with AS7128 conjugated magnetic beads ( Figure 4B and Figure S4C ; NIH-3T3 was loaded as an antibody positive control). This implied that iASPP might be a potential target for AS7128 treatment in lung cancer.
3.5 | AS7128 could restore p53 function through disruption of the interaction between p53 and iASPP A previous study indicated that the expression of iASPP could inhibit cell apoptosis through the binding of p53. 30 We wondered whether AS7128-induced cell apoptosis would result in interruption of the interaction between iASPP and p53. To test this hypothesis, the interaction between iASPP and p53 was detected by co-immunoprecipitation assays with or without AS7128 treated with H460 cells.
The results showed that the binding of iASPP and p53 was inhibited under AS7128 treatment ( Figure 4C ) and also in p53 mutated H1975 cells ( Figure S5 ).
We also examined whether the transactivation activity of p53 could be restored when AS7128 disrupted the iASPP-p53 interaction. As expected, the transactivation activity of p53 could be restored and presented nearly a 1.6-fold increase in the reporter assay ( Figure 4D ). In addition, the mRNA and protein expression Figure S7 ). However, it is very interesting that our protein identification indicated that candidates other than tubulin could be potential targets for AS7128. Using AS7128-conjugated beads and mass spectrometry identification, we found that iASPP was presented in the pull-down complex of AS7128. Previous studies showed that iASPP is overexpressed in NSCLC, gastric cancer and cervical cancer, and it is correlated with pathological stages.
Downregulation of iASPP could inhibit cell proliferation, invasion and migration, and it induced cell apoptosis. 14, [34] [35] [36] Moreover, iASPP could suppress both p53-dependent and independent apoptotic activity through interaction with p53, p63 or p73. [18] [19] [20] Thus, iASPP could be a suitable drug target for lung cancer therapy.
P53 is critical for regulating the cell cycle and apoptosis, and it is also known as a classical tumor suppressor, with over 50% human cancers carrying loss-of-function mutations. 37 We demonstrated that AS7128 could restore the transactivity of p53 through disrupting the interaction between p53 and its inhibitor, hypoxia could induce ischemia. 42 Furthermore, most p53 inhibitors like MDM2 or iASPP are usually overexpressed and act as an oncogene in cancers. 14, 37, 43 Therefore, regulating p53 activity by targeting its inhibitors may be safer than using p53 itself. Thus, developing novel drugs that target iASPP might be a good option for restoring the function of p53 in cancer treatment.
The small peptides 37AA and A34 derived from p53 can increase the expression of p53 downstream genes, dissociate p73 or p53 from iASPP, and suppress tumor growth in vitro and in vivo. 20, 24 Silencing the expressions of iASPP could not only inhibit cell proliferation in vitro and tumor growth in vivo, but also upregulate the mRNA expression levels of p21 and PUMA. 14,34 When we used siRNA to mimic the effect of AS7128 on targeting iASPP, we found that the mRNA and protein levels of BAX and 14-3-3 sigma were also upregulated in iASPP-silenced A549 and H460 cells ( Figure S8 ).
This suggests that iASPP is, indeed, a potential target for inhibiting lung cancer cell growth. Furthermore, miR-124 and miR-140 could regulate the expression levels of iASPP, as well as inhibit tumor growth in cervical cancer and glioma, respectively. 35, 44 We showed that treatment with AS7128 inhibited tumor growth in vitro and in vivo, as well as upregulated the expression levels of p53 downstream genes by disrupting the interaction between p53 and iASPP.
Using a small molecule is a better way to reduce the costs of synthesis and storage and increase the delivery efficiency in clinical applications.
In conclusion, we identified the compound AS7128, which could bind to the oncoprotein iASPP, disrupt the interaction between iASPP and p53, and restore the function of p53 by activating the expression of p53 downstream genes and inducing cell apoptosis.
Because p53 is an important tumor suppressor gene, reactivation of p53 function is proposed as an ideal approach for lung cancer therapy. The identification of AS7128 as an anti-lung cancer small molecule through reactivating p53 by targeting iASPP may provide new insight for further development of lung cancer treatments.
